Pharmacological targeting of GSK3β with selective inhibitors has shown promise in preclinical models, by reducing kidney injury, attenuating renal fibrosis, and promoting renal recovery, positioning GSK3β as a potential therapeutic target for CKD. The gene discussed is GSK3B; the disease is renal fibrosis.